Anaesthetic efficacy and postinduction hypotension with remimazolam compared with propofol : a multicentre randomised controlled trial
© 2024 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of Association of Anaesthetists..
Remimazolam, a short-acting benzodiazepine, may be used for induction and maintenance of total intravenous anaesthesia, but its role in the management of patients with multiple comorbidities remains unclear. In this phase 3 randomised controlled trial, we compared the anaesthetic efficacy and the incidence of postinduction hypotension during total intravenous anaesthesia with remimazolam vs. propofol. A total of 365 patients (ASA physical status 3 or 4) scheduled for elective surgery were assigned randomly to receive total intravenous anaesthesia with remimazolam (n = 270) or propofol (n = 95). Primary outcome was anaesthetic effect, quantified as the percentage of time with Narcotrend® Index values ≤ 60, during surgery (skin incision to last skin suture), with a non-inferiority margin of -10%. Secondary outcome was the incidence of postinduction hypotensive events. Mean (SD) percentage of time with Narcotrend Index values ≤ 60 during surgery across all patients receiving remimazolam (93% (20.7)) was non-inferior to propofol (99% (4.2)), mean difference (97.5%CI) -6.28% (-8.89-infinite); p = 0.003. Mean (SD) number of postinduction hypotension events was 62 (38.1) and 71 (41.1) for patients allocated to the remimazolam and propofol groups, respectively; p = 0.015. Noradrenaline administration events (requirement for a bolus and/or infusion) were also lower in patients allocated to remimazolam compared with propofol (14 (13.5) vs. 20 (14.6), respectively; p < 0.001). In conclusion, in patients who were ASA physical status 3 or 4, the anaesthetic effect of remimazolam was non-inferior to propofol.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Anaesthesia - 79(2024), 4 vom: 26. März, Seite 410-422 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fechner, J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.03.2024 Date Revised 07.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/anae.16205 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367120623 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367120623 | ||
| 003 | DE-627 | ||
| 005 | 20240307232209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240115s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/anae.16205 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1319.xml |
| 035 | |a (DE-627)NLM367120623 | ||
| 035 | |a (NLM)38221513 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fechner, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anaesthetic efficacy and postinduction hypotension with remimazolam compared with propofol |b a multicentre randomised controlled trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2024 | ||
| 500 | |a Date Revised 07.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of Association of Anaesthetists. | ||
| 520 | |a Remimazolam, a short-acting benzodiazepine, may be used for induction and maintenance of total intravenous anaesthesia, but its role in the management of patients with multiple comorbidities remains unclear. In this phase 3 randomised controlled trial, we compared the anaesthetic efficacy and the incidence of postinduction hypotension during total intravenous anaesthesia with remimazolam vs. propofol. A total of 365 patients (ASA physical status 3 or 4) scheduled for elective surgery were assigned randomly to receive total intravenous anaesthesia with remimazolam (n = 270) or propofol (n = 95). Primary outcome was anaesthetic effect, quantified as the percentage of time with Narcotrend® Index values ≤ 60, during surgery (skin incision to last skin suture), with a non-inferiority margin of -10%. Secondary outcome was the incidence of postinduction hypotensive events. Mean (SD) percentage of time with Narcotrend Index values ≤ 60 during surgery across all patients receiving remimazolam (93% (20.7)) was non-inferior to propofol (99% (4.2)), mean difference (97.5%CI) -6.28% (-8.89-infinite); p = 0.003. Mean (SD) number of postinduction hypotension events was 62 (38.1) and 71 (41.1) for patients allocated to the remimazolam and propofol groups, respectively; p = 0.015. Noradrenaline administration events (requirement for a bolus and/or infusion) were also lower in patients allocated to remimazolam compared with propofol (14 (13.5) vs. 20 (14.6), respectively; p < 0.001). In conclusion, in patients who were ASA physical status 3 or 4, the anaesthetic effect of remimazolam was non-inferior to propofol | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a hypotension | |
| 650 | 4 | |a propofol | |
| 650 | 4 | |a remimazolam | |
| 650 | 4 | |a total intravenous anaesthesia | |
| 650 | 7 | |a Propofol |2 NLM | |
| 650 | 7 | |a YI7VU623SF |2 NLM | |
| 650 | 7 | |a remimazolam |2 NLM | |
| 650 | 7 | |a 7V4A8U16MB |2 NLM | |
| 650 | 7 | |a Anesthetics |2 NLM | |
| 650 | 7 | |a Benzodiazepines |2 NLM | |
| 650 | 7 | |a 12794-10-4 |2 NLM | |
| 700 | 1 | |a El-Boghdadly, K |e verfasserin |4 aut | |
| 700 | 1 | |a Spahn, D R |e verfasserin |4 aut | |
| 700 | 1 | |a Motsch, J |e verfasserin |4 aut | |
| 700 | 1 | |a Struys, M M R F |e verfasserin |4 aut | |
| 700 | 1 | |a Duranteau, O |e verfasserin |4 aut | |
| 700 | 1 | |a Ganter, M T |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, T |e verfasserin |4 aut | |
| 700 | 1 | |a Hollmann, M W |e verfasserin |4 aut | |
| 700 | 1 | |a Rossaint, R |e verfasserin |4 aut | |
| 700 | 1 | |a Bercker, S |e verfasserin |4 aut | |
| 700 | 1 | |a Rex, S |e verfasserin |4 aut | |
| 700 | 1 | |a Drexler, B |e verfasserin |4 aut | |
| 700 | 1 | |a Schippers, F |e verfasserin |4 aut | |
| 700 | 1 | |a Morley, A |e verfasserin |4 aut | |
| 700 | 1 | |a Ihmsen, H |e verfasserin |4 aut | |
| 700 | 1 | |a Kochs, E |e verfasserin |4 aut | |
| 700 | 0 | |a Surgery Under Remimazolam - Total IntraVenous Anaesthesia (SURE-TIVA) Trial Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anaesthesia |d 1947 |g 79(2024), 4 vom: 26. März, Seite 410-422 |w (DE-627)NLM000046280 |x 1365-2044 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2024 |g number:4 |g day:26 |g month:03 |g pages:410-422 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/anae.16205 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2024 |e 4 |b 26 |c 03 |h 410-422 | ||